STERIS heads into its fiscal second-quarter report with a full-year promise that leans heavily on the months still ahead. Management has reaffirmed its fiscal 2027 outlook several times, but the math behind that range now depends on a second-half acceleration in sterilization services and capital equipment. That makes this quarter less about a headline beat and more about whether the building blocks for a stronger back half are visibly falling into place.
Wall Street expects earnings of $2.67 per share on revenue of about $1.56 billion, which would be growth of roughly 8% on the bottom line and nearly 7% on the top. That is solid, but it trails the 9% to 11% earnings growth embedded in management's full-year guidance of $11.10 to $11.30 per share on revenue of $6.35 billion to $6.41 billion. The Street's full-year view of $11.17 sits just below the midpoint, and its $6.37 billion revenue estimate sits in the lower half of the range. In other words, analysts believe the guidance but are not paying up for the top end. If the second quarter lands near consensus, STERIS will have earned about $5.26 in the first half, leaving roughly $5.84 to $6.04 for the final two quarters. That implies a meaningful step-up from current quarterly run rates, so the commentary on the second half matters as much as the quarter itself.
The strongest part of last quarter's story was healthcare consumables and service. Management pointed to above-market growth in endoscopy procedures, which make up about a third of the healthcare franchise, and claimed share gains in automated endoscope reprocessors, dedicated chemistries and scope repair. That was a more specific claim than the company had offered before, and this report is the first chance to see whether it holds. Continued strength in recurring consumables and service revenue would validate it, while any softening would sharpen analysts' existing questions about hospital procedure volumes and the payment environment. Healthcare capital equipment was light last quarter on order timing, and with backlog having swelled on a 4% order increase, shipments should start converting. Another quarter of soft capital revenue would make that timing explanation harder to accept.
The applied sterilization technologies business remains the swing factor. Medical device customers are still working down inventory, and the segment faces a tough comparison against 13% growth in the first half of last year. Management has already pushed the expected acceleration to the third quarter while holding its 7% to 8% segment growth target. Nobody should expect a turn this quarter, but any sign that destocking is easing would make the second-half forecast more credible. A suggestion that the recovery could slip again would put the full-year range at real risk.
Margins and cash round out the checklist. Gross margin improved last quarter excluding tariffs, thanks to price and productivity, but tariffs are still costing about $14 million a quarter and only a small slice of potential refunds has arrived. Separately, the new $600 million North Carolina chemistry and sterility assurance plant lifted fiscal 2027 capital spending to about $450 million and cut the free cash flow target to $800 million. Elevated spending is expected to continue into fiscal 2029. Any further slippage in that cash outlook would be unwelcome.
The market has been forgiving so far. Shares have gained about 7% since the last report while the S&P 500 slipped slightly, and the stock trades above its 200-day moving average, though still about 5% below its post-earnings high. Sentiment remains modestly bearish but has improved a little from last quarter. That combination suggests investors have bought into the steady-compounder story without getting euphoric. The verdict will hinge on whether STERIS can show that endoscopy-driven consumables strength is durable and that sterilization services are on track to reaccelerate. If both hold, the back-loaded guidance looks achievable. If either wobbles, a stock that has outperformed could give back some ground.